215 related articles for article (PubMed ID: 19697966)
21. Emerging drugs for asthma.
Walsh GM
Expert Opin Emerg Drugs; 2008 Dec; 13(4):643-53. PubMed ID: 19046132
[TBL] [Abstract][Full Text] [Related]
22. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
23. Tiarellic acid attenuates airway hyperresponsiveness and inflammation in a murine model of allergic asthma.
Lee MY; Ahn KS; Lim HS; Yuk JE; Kwon OK; Lee KY; Lee HK; Oh SR
Int Immunopharmacol; 2012 Jan; 12(1):117-24. PubMed ID: 22085848
[TBL] [Abstract][Full Text] [Related]
24. [Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment].
Fal AM; Kopeć A
Pneumonol Alergol Pol; 2010; 78(1):68-73. PubMed ID: 20162521
[TBL] [Abstract][Full Text] [Related]
25. Cytokines and their receptors as therapeutic targets in asthma.
Pauwels RA; Brusselle GG; Tournoy KG; Lambrecht BN; Kips JC
Clin Exp Allergy; 1998 Aug; 28 Suppl 3():1-5. PubMed ID: 9756180
[TBL] [Abstract][Full Text] [Related]
26. Antileukotriene agents in asthma: the dart that kills the elephant?
Renzi PM
CMAJ; 1999 Jan; 160(2):217-23. PubMed ID: 9951445
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies for the treatment of asthma.
Catley MC; Coote J; Bari M; Tomlinson KL
Pharmacol Ther; 2011 Dec; 132(3):333-51. PubMed ID: 21944943
[TBL] [Abstract][Full Text] [Related]
28. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
Peters MC; Wenzel SE
Lancet; 2020 Feb; 395(10221):371-383. PubMed ID: 32007172
[TBL] [Abstract][Full Text] [Related]
29. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
Fajt ML; Wenzel SE
J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
[TBL] [Abstract][Full Text] [Related]
30. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
31. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma.
Lee M; Kim S; Kwon OK; Oh SR; Lee HK; Ahn K
Int Immunopharmacol; 2009 Apr; 9(4):418-24. PubMed ID: 19185061
[TBL] [Abstract][Full Text] [Related]
32. Ginsenoside Rh2 attenuates allergic airway inflammation by modulating nuclear factor-κB activation in a murine model of asthma.
Li LC; Piao HM; Zheng MY; Lin ZH; Choi YH; Yan GH
Mol Med Rep; 2015 Nov; 12(5):6946-54. PubMed ID: 26502836
[TBL] [Abstract][Full Text] [Related]
33. Targeting airway inflammation: novel therapies for the treatment of asthma.
Walsh GM
Curr Med Chem; 2006; 13(25):3105-11. PubMed ID: 17073650
[TBL] [Abstract][Full Text] [Related]
34. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
35. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.
Herbert C; Hettiaratchi A; Webb DC; Thomas PS; Foster PS; Kumar RK
Clin Exp Allergy; 2008 May; 38(5):847-56. PubMed ID: 18307529
[TBL] [Abstract][Full Text] [Related]
36. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
37. Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma.
Bagnasco D; Caminati M; Ferrando M; Aloè T; Testino E; Canonica GW; Passalacqua G
Biomed Res Int; 2018; 2018():5698212. PubMed ID: 30519580
[TBL] [Abstract][Full Text] [Related]
38. Redefining approaches to asthma: developing targeted biologic therapies.
Arron JR; Scheerens H; Matthews JG
Adv Pharmacol; 2013; 66():1-49. PubMed ID: 23433454
[TBL] [Abstract][Full Text] [Related]
39. Future biologic therapies in asthma.
Quirce S; Bobolea I; Domínguez-Ortega J; Barranco P
Arch Bronconeumol; 2014 Aug; 50(8):355-61. PubMed ID: 24685200
[TBL] [Abstract][Full Text] [Related]
40. Advances in immunopharmacology of asthma.
Wong WS; Koh DS
Biochem Pharmacol; 2000 Jun; 59(11):1323-35. PubMed ID: 10751541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
